OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese  ¹     Brian G. Feagan  ²     Douglas C. Wolf  ³     Stephen B Hanauer  ⁴     Igor Jovanovic  ⁵     Subrata Ghosh  ⁶     AnnKatrin Petersen  ⁷     Steven Y Hua  ⁷     Ji Hwan Lee  ⁷     Lorna Charles  ⁷     Denesh Chitkara  ⁷     William Sandborn  ⁸     Geert R. D'Haens  ^9    
1 Humanitas Clinical and Research Center, Milan, Italy
² Western University, London, Canada
³ Atlanta Gastroenterology Associates, Atlanta, United States
⁴ Feinberg School of Medicine, Chicago, United States
⁵ University Hospital Medical Centre Bezanijska Kosa, Belgrade, Serbia
⁶ University of Calgary, Alberta, Canada
⁷ Bristol-Myers Squibb Company, Princeton, United States
⁸ University of California San Diego, La Jolla, United States
⁹ Amsterdam University Medical Center, Amsterdam, Netherlands

Session
Late breaking abstract: Clinical IBD highlights

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)